Drug updated on 11/13/2023
|Injection (subcutaneous: 125mg/0.5mL, 63mg/0.5mL, 94mg/0.5mL)
|Ongoing and Completed Studies
- For the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Product Monograph / Prescribing Information
|Plegridy (peginterferon beta-1a) Prescribing Information.
|Biogen Inc., Cambridge, MA
Systematic Reviews / Meta-Analyses
|Comparative efficacy and safety of disease-modifying therapies in patients with relapsing multiple sclerosis: A systematic review and network meta-analysis.
|Journal of the American Pharmacists Association
|Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis
|Journal of neurology
Clinical Practice Guidelines
|An update on Peginterferon beta-1a Management in Multiple Sclerosis: results from an interdisciplinary Board of German and Austrian Neurologists and dermatologists
|ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.
|Multiple Sclerosis Journal
|Practice guideline: Disease-modifying therapies for adults with multiple sclerosis.
|American Academy of Neurology